Professor Joanne Bowen

Professor

Health and Medical Sciences Faculty Office

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Joanne Bowen
B.Hlth.Sci (Hons), PhD (Medicine), M.Phil (Clin Sci), Grad.Cert. Public Health, Grad. Cert. Online Learning

Prof Bowen's research focuses on mechanisms and management of cancer therapy-related toxicities, with a special interest in gastrointestinal adverse effects. She was awarded an NHMRC Australian-based Biomedical Training Fellowship (2009 – 2012) to conduct novel research aimed at discovery of peripheral blood biomarkers associated with risk of toxicity during treatment for oesophageal cancer. Her recent work has lead to development of preclinical models for testing interventions for gastrointestinal toxicity utilized by the pharmaceutical industry. She is co-head of the highly active Cancer Treatment Toxicities Group which supports diverse projects across the field of supportive oncology and training of the next generation of researchers.

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

As Head of the Cancer Treatment & Toxicities Group (@ToxicitiesGroup for X updates) in the School of Biomedicine, I am responsible for a program of research aimed at better managing side effects of cancer therapy. Our group investigates both the underlying mechanisms and the treatment approaches to prevention of some of the most common toxicities of cancer therapies including diarrhoea, vomiting, neuroinflammation and bone loss. My particular interest is in how the gastrointestinal tract responds to exposure to chemotherapy, radiation and small molecule inhibitors used in treatment of solid tumours, and how the microbiome can influence the incidence and severity of injury. My current projects focus on establishing new interventions for mitigation of gastrointestinal side effects that target interactions between the gut microbiome and immune system at the level of the mucosal barrier. Our group members include undergraduate students, through to Honours and PhD, as well as postdoctoral researchers. We conduct research projects using cell culture and organoid models, transgenic rodents, and in patient cohorts (detailed below). Our mission is to improve cancer outcomes through personalising treatment and supportive care.

Quantitative microscopy Cell adhesion protein expression Intestinal physiology changes related to diarrhoea

Gut-brain links in treatment toxicities

Images: Techniques and pathways under investigation. Top panel - Quantitiative histology; Cell junctional protein analysis; Intestinal physiology underpinning chemotherapy symptoms. Bottom image - Links between gut toxicity and central neuroinflammation (from group postdoc, Hannah Wardill, Cancer Treat Rev 2015)

Research Project 1

Title: Gut microbiome composition as a predictive marker for cancer treatment outcomes

Project description: Patients with cancer are at high risk of microbiome dysbiosis (lack of bacterial diversity and/or overabundance of pathogenic species) due to frequent hospital visits, surgery, chemotherapy and radiation treatment, other medications (notably prophylactic antibiotics), changes in diet, and the presence of cancer itself. Having a diverse gut microbiota is considered protective against chemotherapy-induced infections, and pre-clinical work points to bacterial diversity as a key determinant of tumour response, gastrointestinal toxicity, and neuroinflammation. Thus the objective of this project is to explore links between microbiota, inflammatory responses, and cancer treatment outcomes. Research techniques include mouse models of cancer treated with chemotherapy, bacterial gene sequencing, and a patient trial analysing longitudinal changes in microbiome composition following different cancer therapies.

Projects available for: Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Research Project 2

Title: Dietary interventions for protection from chemotherapy-induced bone loss

Project description: Drugs used to treat breast cancer cause damage to normal bone structure, leading to adverse symptoms such as loss of bone mineral density and fractures in survivors. Our group is working with industry to explore different dietary interventions to prevent bone loss following treatment with the chemotherapy drug, methotrexate. This project will use breast cancer rodent cancer models treated with chemotherapy. Research techniques include histological analysis, cell death assays, immunofluorescence, real time PCR and small animal handling.

Projects available for: Third Year / Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Research Project 3

Title: The CANnabinoids for CANcer Therapy (CANCAN) Trial

Project description: Medicinal cannabis is being explored as a new treatment for various side effects of cancer treatment. We are conducting a randomised controlled trial in patients with solid tumours who may benefit from a medicinal cannabis product (oral CBD and THC preparations). In addition to measures of effectiveness, the project will explore patient perceptions of the medication, patient-reported outcome measures, and pharmacology of the intervention.

Projects available for: HDR (PhD and M.Phil)

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Appointments

Date Position Institution name

2021 - ongoing Professor University of Adelaide

2017 - 2021 Associate Professor University of Adelaide

Date	Position	Institution name
2021 - ongoing	Professor	University of Adelaide
2017 - 2021	Associate Professor	University of Adelaide

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2016	Award	Telstra Women's Business Public Sector and Academia Award	-	-	-
2014	Award	MASCC Young Investigator Award	-	-	-
2009	Award	SA Young Tall Poppy Science Award	Australian Institute of Policy and Science	-	-
2009	Fellowship	NHMRC Australian-based biomedical research fellowship	University of Adelaide	Australia	-
2008	Award	MASCC Young Investigator Award	-	-	-
2007	Award	MASCC Young Investigator Award	-	-	-
2006	Award	MASCC Young Investigator of the Year	-	-	-
2003	Scholarship	Royal Adelaide Hospital Research Committee Dawes Postgraduate Research Scholarship	-	-	-

Education

Date	Institution name	Country	Title
2010 - 2012	University of Adelaide	Australia	M.Phil (Clin Sci)
2002 - 2006	University of Adelaide	Australia	PhD
1997 - 2001	University of Adelaide	Australia	B. Hlth.Sci (Hons)

Certifications

Date Title Institution name Country

— Grad. Cert. Online Learning (Higher Education) University of Adelaide Australia

— Grad. Cert. Public Health Charles Darwin University Australia
Research Interests

Cancer Therapy Chemotherapy Immunogenetics Microbial Ecology Systems Biology Cancer Biology and Clinical Oncology Neuroscience, Behaviour and Brain Health Nutrition and Metabolic Health Oral Health

Date	Title	Institution name	Country
—	Grad. Cert. Online Learning (Higher Education)	University of Adelaide	Australia
—	Grad. Cert. Public Health	Charles Darwin University	Australia

Journals

Year	Citation
2024	Cross, C., Davies, M., Bateman, E., Crame, E., Joyce, P., Wignall, A., . . . Bowen, J. (2024). Fibre-rich diet attenuates chemotherapy-related neuroinflammation in mice. Brain, Behavior, and Immunity, 115, 13-25. DOI Scopus5 Europe PMC1
2024	Abdalla-Aslan, R., Bonomo, P., Keefe, D., Blijlevens, N., Cao, K., Cheung, Y. T., . . . Nagano, C. (2024). Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine, 73, 102675-1-102675-12. DOI
2024	Dikeocha, I. J., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2024). Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data. Clinical Nutrition ESPEN, 63, 462-475. DOI
2024	Nguyen, T. P. M., Woods, S. L., Secombe, K. R., Tang, S., Elz, A. S., Ayton, S., . . . Bowen, J. M. (2024). Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury. Cancer Chemotherapy and Pharmacology, 94(4), 493-505. DOI
2024	Bowen, J., Braga, S., Zotto, V. D., Finnie, J., DiPrimeo, D., Cooke, B., . . . Di Palma, J. A. (2024). Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib-induced diarrhea in HER2-positive breast cancer-A pilot study.. Physiol Rep, 12(16), e70008. DOI Europe PMC1
2024	Chan, R. J., Knowles, R., Ashbury, F. D., Bowen, J., Chan, A., Chin, M., . . . Lustberg, M. (2024). Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care—an international Delphi study. EClinicalMedicine, 76, 102825-1-102825-12. DOI
2023	Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30. DOI Scopus2 Europe PMC2
2023	Bowen, J., & Cross, C. (2023). The Role of the Innate Immune Response in Oral Mucositis Pathogenesis. International Journal of Molecular Sciences, 24(22), 14 pages. DOI Scopus2 Europe PMC1
2023	Li, A., Bowen, J. M., Ball, I. A., Wilson, S., Yong, A., Yeung, D. T., . . . Wardill, H. R. (2023). Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study. Biomedicines, 11(12), 1-9. DOI Scopus1
2023	Crame, E. E., Nourmohammadi, S., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2023). Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. Journal of Cancer Research and Clinical Oncology, 149(7), 3009-3021. DOI Scopus2 Europe PMC1
2023	Tam, J. S. Y., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2023). Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation. Inflammation, 46(1), 103-114. DOI Scopus5 WoS4 Europe PMC3
2023	Tam, J. S. Y., Pei, J. V., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2023). Structural insight and analysis of TLR4 interactions with IAXO-102, TAK-242 and SN-38: an in silico approach.. In silico pharmacology, 11(1), 1-1-1-9. DOI Europe PMC1
2023	Al-Qadami, G., Bowen, J., Van Sebille, Y., Secombe, K., Dorraki, M., Verjans, J., . . . Le, H. (2023). Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study. Supportive Care in Cancer, 31(1), 98-1-98-14. DOI Scopus16 WoS5 Europe PMC13
2023	Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., . . . Coller, J. K. (2023). Advanced statistics identifcation of participant and treatment predictors associated with severe adverse efects induced by fuoropyrimidine‑based chemotherapy. Cancer Chemother Pharmacol, 91(6), 507-521. DOI Scopus1 Europe PMC1
2023	Wardill, H. R., Da Silva Ferreira, A. R., Kumar, H., Bateman, E. H., Cross, C. B., Bowen, J. M., . . . Tissing, W. J. E. (2023). Whey-based diet containing medium chain triglycerides modulates the gut microbiota and protects the intestinal mucosa from chemotherapy while maintaining therapy efficacy.. Cell Death and Disease, 14(5), 338-1-338-11. DOI Scopus8 WoS1 Europe PMC3
2023	Maddern, A. S., Coller, J. K., Bowen, J. M., & Gibson, R. J. (2023). The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse Effects. Cancers, 15(17), 4301-1-4301-22. DOI Scopus2 Europe PMC1
2022	Tam, J. S. Y., Crame, E. E., Elz, A. S., Coller, J. K., Wignall, A., Prestidge, C. A., & Bowen, J. M. (2022). Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology, 90(3), 267-278. DOI Scopus4 WoS1 Europe PMC2
2022	Harata-Lee, Y., Qu, Z., Bateman, E., Xiao, X., Keller, M. D., Bowen, J., . . . Adelson, D. L. (2022). Compound Kushen injection reduces severity of radiation-induced gastrointestinal mucositis in rats. Frontiers in Oncology, 12, 929735. DOI Scopus5 Europe PMC3
2022	Elz, A. S., Trevaskis, N. L., Porter, C. J. H., Bowen, J. M., & Prestidge, C. A. (2022). Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Journal of Controlled Release, 341, 676-701. DOI Scopus26 Europe PMC12
2022	Bowen, J., & Wardill, H. (2022). The science of mucositis. SUPPORTIVE CARE IN CANCER, 30(4), 3 pages. DOI Scopus1
2022	Al-Qadami, G., Van Sebille, Y., Bowen, J., & Wardill, H. (2022). Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis.. Frontiers in oral health, 3, 1-10. DOI Scopus20 WoS11 Europe PMC12
2022	Al-Qadami, G., Verma, G., Van Sebille, Y., Le, H., Hewson, I., Bateman, E., . . . Bowen, J. (2022). Antibiotic-Induced Gut Microbiota Depletion Accelerates the Recovery of Radiation-Induced Oral Mucositis in Rats.. International journal of radiation oncology, biology, physics, 113(4), 845-858. DOI Scopus10 WoS4 Europe PMC7
2022	Raja Sharin, R. N. F. S., Khan, J., Ibahim, M. J., Muhamad, M., Bowen, J., & Wan Mohamad Zain, W. N. I. (2022). Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review. BioMed Research International, 2022, 1-13. DOI Scopus1
2022	Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2022). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemother Pharmacol, 89(2), 275-281. DOI Scopus5 WoS3 Europe PMC5
2022	Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Keefe, D. M., & Bowen, J. M. (2022). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. Neoplasia, 30, 100806-1-100806-10. DOI Scopus9 WoS4 Europe PMC7
2022	Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022). Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities. Microorganisms, 10(10), 2048. DOI Scopus46 WoS14 Europe PMC34
2022	Subramaniam, C. B., Wardill, H. R., Davies, M. R., Heng, V., Gladman, M. A., & Bowen, J. M. (2022). 5-Fluorouracil Induces an Acute Reduction in Neurogenesis and Persistent Neuroinflammation in a Mouse Model of the Neuropsychological Complications of Chemotherapy. Molecular Neurobiology, 60(3), 1408-1424. DOI Scopus1 WoS1 Europe PMC1
2021	Secombe, K. R., Al-Qadami, G. H., Subramaniam, C. B., Bowen, J. M., Scott, J., Van Sebille, Y. Z. A., . . . Wardill, H. R. (2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes, 13(1), 1979878-1-1979878-15. DOI Scopus43 WoS26 Europe PMC26
2021	Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 1-11. DOI Scopus3 Europe PMC3
2021	Tam, S. Y., Coller, J. K., Hughes, P. A., Prestidge, C. A., & Bowen, J. M. (2021). Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. Indian Journal of Gastroenterology, 40(1), 5-21. DOI Scopus47 WoS26 Europe PMC29
2021	Korver, S., Bowen, J., Pearson, K., Gonzalez, R. J., French, N., Park, K., . . . Goldring, C. (2021). The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Archives of toxicology, 95(11), 3435-3448. DOI Scopus28 WoS15 Europe PMC9
2021	Bruning, E. E., Coller, J. K., Wardill, H. R., & Bowen, J. M. (2021). Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of Cellular Physiology, 236(2), 877-888. DOI Scopus26 WoS12 Europe PMC16
2021	Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Keefe, D. M., & Bowen, J. M. (2021). Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.. Breast Cancer, 28(1), 99-109. DOI Scopus8 WoS3 Europe PMC6
2020	Chow, P. H., Bowen, J., & Yool, A. J. (2020). Combined systematic review and transcriptomic analyses of mammalian aquaporin classes 1 to 10 as biomarkers and prognostic indicators in diverse cancers. Cancers, 12(7), 1-31. DOI Scopus25 WoS18 Europe PMC17
2020	Subramaniam, C. B., Bowen, J. M., Gladman, M. A., Lustberg, M. B., Mayo, S. J., & Wardill, H. R. (2020). The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment. Neuroscience and Biobehavioral Reviews, 116, 470-479. DOI Scopus36 WoS22 Europe PMC21
2020	Wan Mohamad Zain, W. N. I. Z., Bowen, J., Bateman, E., & Keefe, D. (2020). Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines.. Biomedicines, 8(1), 14 pages. DOI Scopus4 WoS3 Europe PMC3
2020	Mayo, B., Secombe, K., Wignall, A., Bateman, E., Thorpe, D., Pietra, C., . . . Bowen, J. (2020). The GLP-2 Analogue Elsiglutide Reduces Diarrhoea Caused by the Tyrosine Kinase Inhibitor Lapatinib in Rats. Cancer Chemotherapy and Pharmacology, 85(4), 793-803. DOI Scopus16 WoS12 Europe PMC13
2020	Secombe, K. R., Van Sebille, Y. Z. A., Mayo, B. J., Coller, J. K., Gibson, R. J., & Bowen, J. M. (2020). Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome.. Integr Cancer Ther, 19, 1534735420928493. DOI Scopus37 WoS26 Europe PMC29
2020	Chiam, K., Mayne, G. C., Wang, T., Watson, D. I., Irvine, T. S., Bright, T., . . . Hussey, D. J. (2020). Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus. World Journal of Gastroenterology, 26(20), 2570-2583. DOI Scopus15 WoS11 Europe PMC15
2020	Wardill, H. R., Sonis, S. T., Blijlevens, N. M. A., Van Sebille, Y. Z. A., Ciorba, M. A., Loeffen, E. A. H., . . . Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). (2020). Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer, 28(11), 5059-5073. DOI Scopus48 WoS29 Europe PMC21
2020	Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431. DOI Scopus329 WoS208 Europe PMC167
2020	Miranda-Silva, W., Gomes-Silva, W., Zadik, Y., Yarom, N., Al-Azri, A. R., Hong, C. H. L., . . . Elad, S. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. SUPPORTIVE CARE IN CANCER, 29(7), 24 pages. DOI Scopus41 WoS28 Europe PMC21
2019	Tam, S. Y. J., Coller, J. K., Wignall, A., Gibson, R. J., Khatri, A., Barbé, C., & Bowen, J. M. (2019). Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis.. Annals of gastroenterology, 32(6), 584-592. DOI Scopus6 WoS4 Europe PMC3
2019	Korver, S. K., Gibson, R. J., Bowen, J. M., & Coller, J. K. (2019). Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.. Cancer Chemotherapy and Pharmacology, 83(2), 217-236. DOI Scopus4 WoS3 Europe PMC1
2019	Secombe, K., Ball, I., Shirren, J., Wignall, A., Finnie, J., Keefe, D., . . . Bowen, J. (2019). Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. Cancer Chemotherapy and Pharmacology, 83(3), 531-543. DOI Scopus14 WoS8 Europe PMC10
2019	Wardill, H. R., Choo, J. M., Dmochowska, N., Mavrangelos, C., Campaniello, M. A., Bowen, J. M., . . . Hughes, P. A. (2019). Acute colitis drives tolerance by persistently altering the epithelial barrier and innate and adaptive immunity. Inflammatory Bowel Diseases, 25(7), 1196-1207. DOI Scopus11 WoS10 Europe PMC8
2019	Al-Qadami, G., Van Sebille, Y., Le, H., & Bowen, J. (2019). Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. Expert Review of Gastroenterology and Hepatology, 13(5), 485-496. DOI Scopus54 WoS30 Europe PMC36
2019	Van Sebille, Y. Z., Gibson, R. J., Wardill, H. R., Carney, T. J., & Bowen, J. M. (2019). Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity.. Experimental biology and medicine (Maywood, N.J.), 244(14), 1178-1185. DOI Scopus16 WoS13 Europe PMC6
2019	Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022. DOI Scopus58 WoS40 Europe PMC28
2019	Bowen, J., Al-Dasooqi, N., Bossi, P., Wardill, H., Van Sebille, Y., Al-Azri, A., . . . Elad, S. (2019). The pathogenesis of mucositis: updated perspectives and emerging targets. Supportive Care in Cancer, 27(10), 4023-4033. DOI Scopus116 WoS84 Europe PMC58
2019	Fakiha, K., Coller, J., Logan, R., Gibson, R., & Bowen, J. (2019). Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis. Supportive Care in Cancer, 27(6), 2313-2320. DOI Scopus9 WoS7 Europe PMC7
2019	Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376. DOI Scopus57 WoS39 Europe PMC29
2019	Lee, A., Bowen, J., Su, Y., Plews, E., Chung, R., Keefe, D. M., & Xian, C. (2019). Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. Journal of Cellular Biochemistry, 120(3), 4180-4191. DOI Scopus4 WoS2 Europe PMC4
2018	Van Sebille, Y., Gibson, R., Wardill, H., Ball, I., Keefe, D., & Bowen, J. (2018). Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. International Journal of Cancer, 142(2), 369-380. DOI Scopus13 WoS12 Europe PMC11
2018	Gibson, R. J., Van Sebille, Y. Z. A., Wardill, H. R., Wignall, A., Shirren, J., Ball, I. A., . . . Bowen, J. M. (2018). Selective MMP inhibition, using AZD3342, to reduce gastrointestinal toxicity and enhance chemoefficacy in a rat model. Chemotherapy, 63(5), 284-292. DOI Scopus5 WoS5 Europe PMC2
2018	Wardill, H. R., Van Sebille, Y. Z. A., Ciorba, M. A., & Bowen, J. M. (2018). Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis. Current Opinion in Supportive and Palliative Care, 12(2), 187-197. DOI Scopus51 WoS40 Europe PMC35
2018	Stansborough, R. L., Al-Dasooqi, N., Bateman, E. H., Bowen, J. M., Keefe, D. M. K., Logan, R. M., . . . Gibson, R. J. (2018). Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. Supportive Care in Cancer, 26(11), 3873-3882. DOI Scopus7 WoS7 Europe PMC4
2018	Stansborough, R. L., Bateman, E. H., Al-Dasooqi, N., Bowen, J. M., Wignall, A., Keefe, D. M., . . . Gibson, R. J. (2018). Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. International Journal of Radiation Biology, 94(7), 645-655. DOI Scopus6 WoS4 Europe PMC4
2018	Khan, S., Wardill, H. R., & Bowen, J. M. (2018). Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. Cancer Chemotherapy and Pharmacology, 82(1), 31-37. DOI Scopus20 WoS15 Europe PMC11
2018	Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15. DOI Scopus15 WoS13 Europe PMC11
2017	Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D., . . . Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140(12), 2820-2829. DOI Scopus27 WoS22 Europe PMC21
2017	Bowen, J. M. (2017). Cancer treatment-related gastrointestinal symptoms. Current Opinion in Supportive and Palliative Care, 11(2), 118-119. DOI Scopus1
2017	Dickenson, A. H., Farquhar-Smith, P., Bannister, K., & Bowen, J. M. (2017). Editorial introductions. CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 11(2), V-VI.
2017	Bowen, J., & Wardill, H. (2017). Advances in the understanding and management of mucositis during stem cell transplantation. Current Opinion in Supportive and Palliative Care, 11(4), 341-346. DOI Scopus38 WoS23 Europe PMC21
2017	Campbell, J., Stephenson, M., Bateman, E., Peters, M., Keefe, D., & Bowen, J. (2017). Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics Journal, 17(1), 21-28. DOI Scopus53 WoS44 Europe PMC30
2017	Al-Dasooqi, N., Bowen, J., Bennett, C., Finnie, J., Keefe, D., & Gibson, R. (2017). Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. Supportive Care in Cancer, 25(2), 391-398. DOI Scopus6 WoS5 Europe PMC3
2017	Mayo, B., Stringer, A., Bowen, J., Bateman, E., & Keefe, D. (2017). Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemotherapy and Pharmacology, 79(2), 233-249. DOI Scopus17 WoS13 Europe PMC11
2017	Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434. DOI Scopus8 WoS7 Europe PMC6
2017	Wardill, H., Bowen, J., Van Sebille, Y., & Gibson, R. (2017). Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. Gut, 66(10), 1869-1871. DOI Scopus3 WoS3 Europe PMC2
2017	Stansborough, R., Bateman, E., Al-Dasooqi, N., Bowen, J., Keefe, D., Yeoh, A., . . . Gibson, R. (2017). Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. Supportive Care in Cancer, 25(6), 1973-1983. DOI Scopus14 WoS13 Europe PMC12
2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Logan, R., & Bowen, J. (2016). A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 241(13), 1386-1394. DOI Scopus7 WoS7 Europe PMC5
2016	Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2016). Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Supportive and Palliative Care, 10(2), 152-156. DOI Scopus7 WoS6 Europe PMC5
2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386. DOI Scopus111 WoS82 Europe PMC71
2016	Wardill, H., Mander, K., Van Sebille, Y., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2016). Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. International Journal of Cancer, 139(12), 2635-2645. DOI Scopus117 WoS85 Europe PMC70
2016	Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779. DOI Scopus42 WoS33 Europe PMC19
2016	Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258. DOI Scopus20 WoS20 Europe PMC10
2016	Wardill, H., Logan, R., Bowen, J., Van Sebille, Y., & Gibson, R. (2016). Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Supportive Care in Cancer, 24(4), 1779-1788. DOI Scopus15 WoS13 Europe PMC8
2015	Wardill, H. R., Logan, R. M., Bowen., & Gibson. (2015). Chemotherapy causes tight junction defects in the oral cavity of patients which co-incide with elevated pro inflammatory cytokines and MMPs. Australian Dent, 60(4).
2015	Campbell, J., Bateman, E., Stephenson, M., Bowen, J., Keefe, D., & Peters, M. D. (2015). Methotrexate-induced Toxicity Pharmacogenetics; an Umbrella Review of Systematic reviews and Meta-analyses. Tumor Biology: from basic science to clinical application, 78(1), 27-39. DOI Scopus52 WoS42 Europe PMC20
2015	Campbell, J., Bateman, E., Peters, M. D., Bowen, J., Keefe, D., & Stephenson, M. (2015). Fluoropyrimidine and Platinum Toxicity Pharmacogenetics: an Umbrella Review of Systematic reviews and Meta-analyses. FutureMedicine Pharmacogenomics, 17(4), 435-451. DOI Scopus32 WoS20 Europe PMC19
2015	Bowen, J., White, I., Smith, L., Tsykin, A., Kristaly, K., Thompson, S., . . . Keefe, D. (2015). Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. Supportive Care in Cancer, 23(11), 3165-3172. DOI Scopus9 WoS6 Europe PMC7
2015	Saunders, D. P., Epstein, J. B., Elad, S., Allemano, J., Bossi, P., van de Wetering, M. D., . . . Lalla, R. V. (2015). Erratum to: Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients [Support Care Cancer, DOI 10.1007/s00520-013-1871-y]. Supportive Care in Cancer, 23(2), 601-602. DOI Scopus1 WoS2
2015	Wardill, H. R., Van Sebille, Y. Z., Bowen, J. M., & Gibson, R. J. (2015). Editorial comment: does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner?. Current Opinion in Supportive and Palliative Care, 9(2), 155-156. DOI Scopus1 WoS1
2015	Chiam, K., Wang, T., Watson, D., Mayne, G., Irvine, T., Bright, T., . . . Hussey, D. (2015). Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. Journal of Gastrointestinal Surgery, 19(7), 1208-1215. DOI Scopus119 WoS107 Europe PMC90
2015	Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2015). ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treatment Reviews, 41(7), 646-652. DOI Scopus50 WoS39 Europe PMC31
2015	Gibson, R. J., Bowen, J. M., & Coller, J. K. (2015). What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?. Future Oncology, 11(17), 2367-2370. DOI Scopus10 WoS9 Europe PMC9
2015	Wardill, H., Van Sebille, Y., Mander, K., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2015). Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treatment Reviews, 41(2), 122-128. DOI Scopus32 WoS30 Europe PMC22
2015	Coller, J., White, I., Logan, R., Tuke, J., Richards, A., Mead, K., . . . Bowen, J. (2015). Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Supportive Care in Cancer, 23(5), 1233-1236. DOI Scopus19 WoS16 Europe PMC10
2015	Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . Elad, S. (2015). Erratum: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy (Cancer (2014) 120 (1453-1661)). Cancer, 121(8), 1339. DOI WoS2
2015	Al-Azri, A. R., Gibson, R. J., Bowen, J. M., Stringer, A. M., Keefe, D. M., & Logan, R. M. (2015). Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. Journal of Oral Pathology & Medicine, 44(6), 459-467. DOI Scopus29 WoS28 Europe PMC16
2014	Wardill, H. R., Bowen, J. M., & Gibson, R. J. (2014). New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opinion on Biological Therapy, 14(3), 347-354. DOI Scopus15 WoS14 Europe PMC10
2014	Wardill, H., Bowen, J., Al-Dasooqi, N., Sultani, M., Bateman, E., Stansborough, R., . . . Gibson, R. (2014). Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biology and Therapy, 15(2), 236-244. DOI Scopus64 WoS53 Europe PMC41
2014	Bowen, J., Mayo, B., Plews, E., Bateman, E., Wignall, A., Stringer, A., . . . Keefe, D. (2014). Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemotherapy and Pharmacology, 74(3), 617-627. DOI Scopus23 WoS17 Europe PMC15
2014	Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., . . . The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 120(10), 1453-1461. DOI Scopus843 WoS619 Europe PMC481
2014	Bowen, J. (2014). Development of the rat model of lapatinib-induced diarrhoea. Scientifica, 2014, 194185-1-194185-6. DOI WoS9 Europe PMC6
2014	Wardill, H., Gibson, R., Logan, R., & Bowen, J. (2014). TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?. International Journal of Cancer, 135(11), 2483-2492. DOI Scopus31 WoS27 Europe PMC16
2014	Savas, P., Robertson, A., Beatty, L., Hookings, E., Mcgee, M., Marker, J., . . . Koczwara, B. (2014). Patient preferences on the integration of complementary therapy with conventional cancer care. Asia-Pacific Journal of Clinical Oncology, 12(2), 1-8. DOI Scopus9 WoS7 Europe PMC5
2014	Van Sebille, Y., Gibson, R., & Bowen, J. (2014). IS CROFELEMER AN EFFECTIVE INTERVENTION FOR DACOMITINIB-INDUCED GASTROINTESTINAL TOXICITY?. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, 208-209.
2013	Yarom, N., Ariyawardana, A., Hovan, A., Barasch, A., Jarvis, V., Jensen, S., . . . Lalla, R. (2013). Systematic review of natural agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3209-3221. DOI Scopus96 WoS76 Europe PMC54
2013	Jensen, S., Jarvis, V., Zadik, Y., Barasch, A., Ariyawardana, A., Hovan, A., . . . Elad, S. (2013). Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3223-3232. DOI Scopus44 WoS34 Europe PMC27
2013	McGuire, D., Fulton, J., Park, J., Brown, C., Correa, M., Eilers, J., . . . Lalla, R. (2013). Systematic review of basic oral care for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3165-3177. DOI Scopus180 WoS141 Europe PMC101
2013	Saunders, D., Epstein, J., Elad, S., Allemano, J., Bossi, P., van de Wetering, M., . . . Lalla, R. (2013). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3191-3207. DOI Scopus126 WoS88 Europe PMC59
2013	Nicolatou-Galitis, O., Sarri, T., Bowen, J., Di Palma, M., Kouloulias, V., Niscola, P., . . . Lalla, R. (2013). Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(11), 3179-3189. DOI Scopus91 WoS67 Europe PMC52
2013	Bateman, E., Bowen, J., Stringer, A., Mayo, B., Plews, E., Wignall, A., . . . Keefe, D. (2013). Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients, 5(10), 3948-3963. DOI Scopus9 WoS9 Europe PMC8
2013	Wardill, H., & Bowen, J. (2013). Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Current Opinion in Supportive and Palliative Care, 7(2), 155-161. DOI Scopus50 WoS47 Europe PMC34
2013	Bowen, J. (2013). Mechanisms of TKI-induced diarrhea in cancer patients. Current Opinion in Supportive and Palliative Care, 7(2), 162-167. DOI Scopus56 WoS45 Europe PMC36
2013	Al-Dasooqi, N., Sonis, S., Bowen, J., Bateman, E., Blijlevens, N., Gibson, R., . . . Lalla, R. (2013). Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 21(7), 2075-2083. DOI Scopus125 WoS103 Europe PMC70
2013	Wardill, H., Bowen, J., & Gibson, R. (2013). Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. The Journal of Supportive Oncology, 11(2), 61-67. DOI Scopus13 Europe PMC8
2013	Stringer, A., Al-Dasooqi, N., Bowen, J., Tan, T., Radzuan, M., Logan, R., . . . Gibson, R. (2013). Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Supportive Care in Cancer, 21(7), 1843-1852. DOI Scopus105 WoS94 Europe PMC74
2013	Nicolatou-Galitis, O., Sarri, T., Bowen, J., Palma, M., Kouloulias, V., Niscola, P., . . . Lalla, R. (2013). Systematic review of amifostine for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 357-364. DOI Scopus92 WoS76 Europe PMC46
2013	Raber-Durlacher, J., von Bultzingslowen, I., Logan, R., Bowen, J., Al-Azri, A., Everaus, H., . . . Lalla, R. (2013). Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 343-355. DOI Scopus106 WoS79 Europe PMC68
2013	Migliorati, C., Hewson, I., Lalla, R., Antunes, H., Estilo, C., Hodgson, B., . . . Elad, S. (2013). Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21(1), 333-341. DOI Scopus187 WoS150 Europe PMC109
2013	Peterson, D., Ohrn, K., Bowen, J., Fliedner, M., Lees, J., Loprinzi, C., . . . Lalla, R. (2013). Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Supportive Care in Cancer, 21(1), 327-332. DOI Scopus108 WoS81 Europe PMC66
2013	Gibson, R., Keefe, D., Lalla, R., Bateman, E., Blijlevens, N., Fijlstra, M., . . . Bowen, J. (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Supportive Care in Cancer, 21(1), 313-326. DOI Scopus176 WoS152 Europe PMC109
2013	Elad, S., Bowen, J., Zadik, Y., & Lalla, R. (2013). Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Supportive Care in Cancer, 21(1), 309-312. DOI Scopus27 WoS27 Europe PMC16
2013	Bowen, J., Elad, S., Hutchins, R., & Lalla, R. (2013). Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Supportive Care in Cancer, 21(1), 303-308. DOI Scopus40 WoS38 Europe PMC26
2013	Al-Dasooqi, N., Sonis, S., Bowen, J., Bateman, E., Blijlevens, N., Gibson, R., . . . Lalla, R. (2013). Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 21(11), 3233-3241. DOI Scopus95 WoS76 Europe PMC63
2012	Wardill, H., Bowen, J., & Gibson, R. (2012). Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. Cancer Chemotherapy and Pharmacology, 70(5), 627-635. DOI Scopus33 WoS32 Europe PMC24
2012	Bowen, J., Mayo, B., Plews, E., Bateman, E., Stringer, A., Boyle, F., . . . Keefe, D. (2012). Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biology & Therapy, 13(13), 1269-1275. DOI Scopus31 WoS28 Europe PMC28
2012	Sultani, M., Stringer, A., Bowen, J., & Gibson, R. (2012). Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemotherapy Research and Practice, 2012, 1-11. DOI Europe PMC58
2012	Lalla, R., Bowen, J., & Elad, S. (2012). Mouth care protocol for oral mucositis. Journal of Oncology Pharmacy Practice, 18(1), 158. DOI
2011	Keefe, D., Bowen, J., Gibson, R., Tan, T., Okera, M., & Stringer, A. (2011). Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. The Oncologist, 16(4), 432-444. DOI Scopus82 WoS62 Europe PMC42
2011	Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2011). Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy, 57(1), 43-53. DOI Scopus15 WoS14 Europe PMC11
2011	Bowen, J., Gibson, R., & Keefe, D. (2011). Animal models of mucositis: Implications for therapy. The Journal of Supportive Oncology, 9(5), 161-168. DOI Scopus56 Europe PMC37
2011	Gibson, R., & Bowen, J. (2011). Biomarkers of regimen-related mucosal injury. Cancer Treatment Reviews, 37(6), 487-493. DOI Scopus35 WoS33 Europe PMC27
2011	Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2011). Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. International Journal of Experimental Pathology, 92(5), 357-365. DOI Scopus36 WoS30 Europe PMC28
2010	Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Experimental Biology and Medicine (Maywood), 235(10), 1244-1256. DOI Scopus58 WoS48 Europe PMC42
2010	Ong, Z., Gibson, R., Bowen, J., Stringer, A., Darby, J., Logan, R., . . . Keefe, D. (2010). Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiation Oncology, 5(22), 1-8. DOI Scopus115 WoS100 Europe PMC71
2010	Bowen, J., Tsykin, A., Stringer, A., Logan, R., Gibson, R., & Keefe, D. (2010). Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology, 269(1), 1-12. DOI Scopus11 WoS8 Europe PMC7
2010	Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases and their inhibitors are altered in a time-course model of irinotecan-induced mucositis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25(s3), A2. DOI
2009	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Laurence, J., & Keefe, D. (2009). Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemotherapy and Pharmacology, 64(1), 123-132. DOI Scopus69 WoS63 Europe PMC47
2009	Al-Dasooqi, N., Bowen, J., Gibson, R., Sullivan, T., Lees, J., & Keefe, D. (2009). Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investigational New Drugs, 27(2), 173-178. DOI Scopus27 WoS14 Europe PMC15
2009	Stringer, A., Gibson, R., Bowen, J., Logan, R., Ashton, K., Yeoh, A., . . . Keefe, D. (2009). Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. International Journal of Experimental Pathology, 90(5), 489-499. DOI Scopus123 WoS104 Europe PMC79
2009	Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2009). HER2 targeted therapies for cancer and the gastrointestinal tract. Current Drug Targets, 10(6), 537-542. DOI Scopus18 WoS17 Europe PMC11
2009	Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2009). Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?. Cancer Chemotherapy and Pharmacology, 64(1), 1-9. DOI Scopus39 WoS37 Europe PMC23
2009	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Hamilton, J., & Keefe, D. (2009). Gastrointestinal Microflora and Mucins May Play a Critical Role in the Development of 5-Fluorouracil-Induced Gastrointestinal Mucositis. Experimental Biology and Medicine (Maywood), 234(4), 430-441. DOI Scopus185 WoS158 Europe PMC106
2009	Stringer, A., Gibson, R., Bowen, J., & Keefe, D. (2009). Chemotherapy-induced modifications to gastrointestinal microflora: Evidence and implications of change. Current Drug Metabolism, 10(1), 79-83. DOI Scopus95 WoS83 Europe PMC61
2009	Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). The importance of the gut microbiome in gastrointestinal mucositis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24, A237.
2009	Logan, R., Stringer, A., Bowen, J., Gibson, R., Sonis, S., & Keefe, D. (2009). Is the pathobiology of chemotherapy-induced alimentary tract mucositis inXuenced by the type of mucotoxic drug administered?. Cancer Chemotherapy and Pharmacology, 63(2), 239-251. DOI Scopus142 WoS124 Europe PMC93
2008	Logan, R., Gibson, R., Bowen, J., Stringer, A., Sonis, S., & Keefe, D. (2008). Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemotherapy and Pharmacology, 62(1), 33-41. DOI Scopus161 WoS142 Europe PMC130
2008	Bowen, J., & Keefe, D. (2008). New pathways for alimentary mucositis. Journal of Oncology, 2008, 1-7. DOI WoS21 Europe PMC8
2008	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., & Keefe, D. (2008). Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biology & Therapy, 7(12), 1919-1925. DOI Scopus157 WoS125 Europe PMC100
2008	Gibson, R., Bowen, J., & Keefe, D. (2008). Technological advances in mucositis research: New insights and new issues. Cancer Treatment Reviews, 34(5), 476-482. DOI Scopus17 WoS15 Europe PMC8
2008	Bowen, J. (2008). Prevention and treatment of regimen-related mucosal toxicity. Recent Patents on Anti-Cancer Drug Discovery, 3(2), 68-75. DOI Scopus3 WoS3 Europe PMC2
2008	Keefe, D., Sonis, S., & Bowen, J. (2008). Emerging drugs for chemotherapy-induced mucositis. Expert Opinion on Emerging Drugs, 13(3), 511-522. DOI Scopus42 WoS37 Europe PMC25
2008	Logan, R., Stringer, A., Bowen, J., Gibson, R., Sonis, S., & Keefe, D. (2008). Serum levels of NF kappa B and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biology & Therapy, 7(7), 1139-1145. DOI Scopus151 WoS124 Europe PMC100
2007	Bowen, J., Gibson, R., Stringer, A., Chan, T., Prabowo, A., Cummins, A., & Keefe, D. (2007). Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anti-Cancer Drugs, 18(2), 197-210. DOI Scopus23 WoS20 Europe PMC16
2007	Stringer, A., Gibson, R., Logan, R., Bowen, J., Yeoh, A., Burns, J., & Keefe, D. (2007). Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Experimental Biology and Medicine (Maywood), 232(1), 96-106. Scopus95 WoS73 Europe PMC47
2007	Bowen, J., Stringer, A., Gibson, R., Yeoh, A., Hannam, S., & Keefe, D. (2007). VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. Cancer Biology & Therapy, 6(9), 1449-1454. DOI Scopus170 WoS145 Europe PMC101
2007	Stringer, A., Gibson, R., Bowen, J., Logan, R., Yeoh, A., & Keefe, D. (2007). Chemotherapy-induced mucositis: The role of gastrointestinal microflora and mucins in the luminal environment. The Journal of Supportive Oncology, 5(6), 259-267. Scopus71 Europe PMC41
2007	Bowen, J., Gibson, R., Cummins, A., Tyskin, A., & Keefe, D. (2007). Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemotherapy and Pharmacology, 59(3), 337-348. DOI Scopus37 WoS33 Europe PMC24
2007	Logan, R., Stringer, A., Bowen, J., Yeoh, A., Gibson, R., Sonis, S., & Keefe, D. (2007). The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews, 33(5), 448-460. DOI Scopus230 WoS201 Europe PMC161
2007	Bowen, J., Gibson, R., Tsykin, A., Stringer, A., Logan, R., & Keefe, D. (2007). Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. International Journal of Cancer, 121(8), 1847-1856. DOI Scopus40 WoS39 Europe PMC30
2007	Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., & Keefe, D. (2007). A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis p53 nuclear factor-kappa B COX-1 and COX-2. Molecular Cancer Therapeutics, 6(8), 2319-2327. DOI Scopus51 WoS44 Europe PMC39
2007	Gibson, R., Stringer, A., Bowen, J., Logan, R., Yeoh, A., Burns, J., . . . Keefe, D. (2007). Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biology & Therapy, 6(4), 541-547. DOI Scopus14 WoS12 Europe PMC7
2007	Gibson, R., Bowen, J., Alvarez, E., Finnie, J., & Keefe, D. (2007). Establishment of a Single-Dose Irinotecan Model of Gastrointestinal Mucositis. Chemotherapy, 53(5), 360-369. DOI Scopus58 WoS45 Europe PMC36
2006	Gibson, R., Cummins, A., Bowen, J., Logan, R., Healey, T., & Keefe, D. (2006). Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia Pacific Journal of Clinical Oncology, 2(1), 39-49. DOI Scopus25
2006	Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., . . . Keefe, D. (2006). Radiation therapy-induced mucositis: Relationships between fractionated radiation, NF-kappa B, COX-1, and COX-2. Cancer Treatment Reviews, 32(8), 645-651. DOI Scopus44 WoS38 Europe PMC24
2006	Anthony, L., Bowen, J., Garden, A., Hewson, I., & Sonis, S. (2006). New thoughts on the pathobiology of regimen-related mucosal injury. Supportive Care in Cancer, 14(6), 516-518. DOI Scopus38 WoS25 Europe PMC30
2006	Bowen, J., Gibson, R., Cummins, A., & Keefe, D. (2006). Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Supportive Care in Cancer, 14(7), 713-731. DOI Scopus99 WoS90 Europe PMC66
2006	Bowen, J. M., Gibson, R. J., Cummins, A. G., Tyskin, A., & Keefe, D. M. K. (2006). Irinotecan-induced changes in gene expression in the small intestine of the rat with cancer. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A275.
2006	Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., & Keefe, D. M. K. (2006). Chemotherapy-induced changes in mucin secretion and composition. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A266. WoS2
2006	Yeoh, A., Gibson, R., Yeoh, E., Bowen, J., Stringer, A., Giam, K., & Keefe, D. (2006). A novel animal model to investigate radiation-induced mucositis: a qualitative assessment of mucosal injury resulting from fractionated radiotherapy. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, A260.
2005	Bowen, J. M., Newbold, K., Blake, P., Wild, G., Egner, W., Norman, A. R., & Andreyev, H. J. N. (2005). Do serum levels of eosinophil granule-derived protein change in patients undergoing pelvic radiotherapy?. Clinical Oncology, 17(5), 382-384. DOI Scopus5 Europe PMC4
2005	Yeoh, A., Bowen, J., Gibson, R., & Keefe, D. (2005). Nuclear factor kB (NFkB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. International Journal of Radiation Oncology Biology Physics, 63(5), 1295-1303. DOI Scopus77 WoS66 Europe PMC57
2005	Gibson, R., Bowen, J., Cummins, A., & Keefe, D. (2005). Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clinical and Experimental Medicine, 4(4), 188-195. DOI Scopus44 WoS37 Europe PMC27
2005	Gibson, R., Bowen, J., & Keefe, D. (2005). Palifermin reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats. International Journal of Cancer, 116(3), 464-470. DOI Scopus69 WoS67 Europe PMC44
2005	Bowen, J., Gibson, R., Keefe, D., & Cummins, A. (2005). Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology, 37(1), 56-62. DOI Scopus74 WoS69 Europe PMC50
2003	Gibson, R., Bowen, J., Inglis, M., Cummins, A., & Keefe, D. (2003). Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. Journal of Gastroenterology and Hepatology, 18(9), 1095-1100. DOI Scopus168 WoS148 Europe PMC114

Book Chapters

Year	Citation
2021	Bowen, J. (2021). Being a leader. In K. Jarrett, & S. Newton (Eds.), The Practice of Leadership in Higher Education: Real-world Perspectives on Becoming, Being and Leaving (pp. 206-210). London, United Kingdom: Routledge. DOI
2013	Gibson, R., Bowen, J., Bateman, E., & Keefe, D. (2013). Biology of treatment-induced mucositis. In A. Berger, J. Shuster, & J. Von Roenn (Eds.), Principles and practice of palliative oncology and supportive oncology (4th ed., pp. 238-246). Lippincott Williams & Wilkins.
2012	Al-Dasooqi, N., Gibson, R., Bowen, J., & Keefe, D. (2012). HER2 targeted therapy-induced gastrointestinal toxicity: from the clinical experience to possible molecular mechanisms. In D. Whitehouse, & R. Rapley (Eds.), Molecular and Cellular Therapeutics (1 ed., pp. 69-102). United Kingdom: Wiley. DOI
2008	Keefe, D., Bowen, J., & Gibson, R. (2008). Use of project teams in preclinical development. In S. Gad (Ed.), Preclinical Development Handbook: Toxicology (pp. 65-80). USA and Canada: Wiley. DOI
2008	Gibson, R., Bowen, J., & Keefe, D. (2008). Relationship between animal models and clinical research: using mucositis as a practical example. In S. Gad (Ed.), Preclinical Development Handbook: Toxicology (pp. 81-101). USA and Canada: Wiley. DOI Scopus1

Conference Papers

Year	Citation
2021	Al-Qadami, G., Bowen, J., Van Sebille, Y., Wardill, H., Secombe, K., & Le, H. (2021). Pre-treatment gut microbiome and radiotherapy response and toxicities among patients with head and neck cancer. In MASCC/ISOO Annual Meeting.
2021	Subramaniam, C. B., Wardill, H. R. R., Gladman, M. A., & Bowen, J. M. (2021). 5-FU induces acute neurodegeneration followed by persistent neuroinflammation: A new mechanistic hypothesis for the neurological complications of cancer therapy. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 113). WILEY.
2021	Crame, E., Wardill, H. R., Secombe, K., Coller, J., & Bowen, J. (2021). Intestinal epithelial TLR4 are crucial to chemotherapy toxicity development. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 110). WILEY.
2019	Bowen, J. M., Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Finnie, J. W., . . . Keefe, D. (2019). Budesonide and colesevelam reduce neratinib-induced diarrhea in a rat model. In CANCER RESEARCH Vol. 79 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH. DOI
2019	Bruning, E., Coller, J., Wardill, H., Secombe, K., & Bowen, J. (2019). Toll-like receptor 4 humanized C57BL/6 mouse intestinal permeability: A translational model for cancer treatment toxicity. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 34 (pp. 166). WILEY.
2018	Wardill, H., Secombe, K., Gibson, R., Stringer, A., Al-Dasooqi, N., Mayo, B., & Bowen, J. (2018). Pre-treatment blautia abundance regulates chemo-toxicity in colorectal cancer patients: A pilot study. In NEUROGASTROENTEROLOGY AND MOTILITY Vol. 30 (pp. 1 page). WILEY.
2018	Hughes, P., Wardill, H., Choo, J., Dmochowska, N., Campaniello, M., Mavrangelos, C., . . . Rogers, G. (2018). Acute colitis chronically alters epithelial barrier and adaptive and innate immune responses to subsequent colitis re-activation independently of shifts in microbiota composition. In NEUROGASTROENTEROLOGY AND MOTILITY Vol. 30 (pp. 1 page). WILEY.
2018	Secombe, K., Bowen, J., Coller, J., Gibson, R., Stringer, A., Al-Dasooqi, N., . . . Wardill, H. R. (2018). Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 59). WILEY. WoS1
2018	Korver, S. K., Bowen, J. M., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R., . . . Coller, J. K. (2018). Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 58-59). WILEY.
2015	Vanhoecke, B., Mayo, B., Wignall, A., Ziegler, V., Stringer, A., Bateman, E., . . . Keefe, D. (2015). Irinotecan induces DNA damage in the oral cavitiy of the Dark Agouti rats without visual signs of lesions. In Supportive Care in Cancer Vol. 23 (pp. S115). Copenhagen, Denmark: Springer Verlag (Germany). DOI
2015	Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2015). Investigation of lapatinib-induced diarrhea in a tumour-bearing rat model. In Supportive Care in Cancer Vol. 23 (pp. S387). Copenhagen, Denmark: Springer Verlag (Germany). DOI
2015	Mayo, B., Stringer, A., Lucchesi, C., Bowen, J., Bateman, E., Wignall, A., . . . Keefe, D. (2015). Microbial alterations and toll-like receptor expression play a role in the improvement of irinotecan-induced mucositis after treatment with the new selective GLP-2 receptor agonist, Elsiglutide. In Supportive Care in Cancer Vol. 23 (pp. S111). Copenhagen, Denmark: Springer Verlag (Germany). DOI
2013	Al-Azri, A. S., Logan, R., Gibson, R., Keefe, D., stringer, A., & Bowen, J. (2013). The role of matrix metalloproteinases and tissue inhibitors of metalloproteinase in irinotecan induced-chemotherapy. In Supportive Care in Cancer. Berlin Genrmany: Springer Verlag (Germany).
2013	Abstracts of the MASCC/ISOO (Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology) International Symposium on Supportive Care in Cancer. June 27-29, 2013. Berlin, Germany. (2013). In Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Vol. 21 Suppl 1 (pp. S2-301). Germany: Springer Science and Business Media LLC. DOI Europe PMC2
2012	Abstracts of the 2012 International MASCC/ISOO (Multiple Association of Supportive Care in Cancer/International Society for Oral Oncology) Symposium. New York City, New York, USA. June 28-30, 2012. (2012). In Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Vol. 20 Suppl 1 (pp. 1-283). Germany: Springer Science and Business Media LLC. DOI Europe PMC1
2010	Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2010). Irinotecan-induced mucositis encompasses changes in intestinal and colonic cell kinetics and this is associated with altered extracellular matrix component expression. In Abstracts of the 2010 International MASCC/ISOO Symposium Vol. 25 (pp. 0 pages). Vancouver, Canada: Springer-Verlag. DOI
2010	Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases play a pivotal role in the development of alimentary tract mucositis. In Sydney Cancer Conference (pp. 0 pages). The University of Sydney, NSW, Australia.
2009	Stringer, A., Gibson, R., Yeoh, A., Bowen, J., Logan, R., & Keefe, D. (2009). CHEMOTHERAPY-INDUCED DIARRHOEA IS ASSOCIATED WITH A MODIFIED MICROBIOME IN GI CANCER PATIENTS. In ANNALS OF ONCOLOGY Vol. 20 (pp. 73). Barcelona, SPAIN: OXFORD UNIV PRESS.
2007	Logan, R., Gibson, R., Stringer, A., Bowen, J., Sonis, S., & Keefe, D. (2007). Serum levels of nuclear factor-κB and tumour necrosis factor following irinotecan administration in the Dark Agouti rat. In ORAL ONCOLOGY (pp. 211). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV.
2007	Logan, R., Gibson, R., Stringer, A., Bowen, J., Sonis, S., & Keefe, D. (2007). Nuclear factor-KB and cyclooxygenase-2 expression in the oral mucosa following cancer chemotherapy. In ORAL ONCOLOGY (pp. 171). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV.

Conference Items

Year	Citation
2021	Al-Qadami, G., Verma, G., Van Sebille, Y., Le, H., Hewson, I., & Bowen, J. (2021). Antibiotic-induced depletion of gut microbiota reduces injury area and duration of radiation-induced oral mucositis in rats. Poster session presented at the meeting of Abstracts of the MASCC/ISOO Annual Meeting 2021, as published in Supportive Care in Cancer. virtual online: Springer. DOI
2021	Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Diala, I., Lalani, A. S., & Bowen, J. M. (2021). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.. Poster session presented at the meeting of CANCER RESEARCH. Philadelphia, PA: AMER ASSOC CANCER RESEARCH.
2020	Al-Qadami, G., Van Sebille, Y., Le, H., Hewson, I., & Bowen, J. (2020). Antibiotic-induced depletion of gut microbiota: Impact on radiation-induced oral mucositis in rats. Poster session presented at the meeting of Federation of Neurogastroenterology & Motility.
2019	Al-Qadami, G., Van Sebille, Y., Le, H., Hewson, I., & Bowen, J. (2019). Antibiotic‐induced depletion of gut microbiota: Impact on radiation‐induced oral mucositis in rats. Poster session presented at the meeting of Clinical Oncology Society of Australia.
2019	Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Wardill, H. R., Van Sebille, Y. Z. A., & Bowen, J. M. (2017). Budesonide Reduces Neratinib-Induced Gastrointestinal Injury and Diarrhoea in Rats. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. WoS2
2017	Bowen, J., Ball, I., Thompson, S., Irvine, T., Chiam, K., Hussey, D., . . . Keefe, D. (2017). Identification of Inflammatory Markers of Chemoradiotherapy-Induced Gastrointestinal Toxicity in Oesophageal Cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017	Wardill, H., Bowen, J., Dmochowska, N., Campaniello, M., Mavrangelos, C., Holloway, R., . . . Hughes, P. (2017). Faecal supernatants from diarrhoea predominant Irritable Bowel Syndrome (IBS) patients disrupt colonic epithelial barrier function and directly activate colo-rectal afferent nerves. Poster session presented at the meeting of Abstracts of the NeuroGASTRO 2017 Congress, as published in Neurogastroenterology and Motility. Cork, Ireland: Wiley. DOI
2017	Wardill, H. R., Dmochowska, N., Campaniello, M. A., Mavrangelos, C., Bowen, J. M., Andrews, J. M., . . . Hughes, P. A. (2017). Fecal supernatants from active ulcerative colitis patients impair colonic epithelial barrier integrity and activate pelvic mucosal extrinsic afferent nerves. Poster session presented at the meeting of FASEB Journal. Chicago, IL: Federation of American Societies for Experimental Biology.
2014	Mayo, B., Stringer, A., Bateman, E., Bowen, J., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley. DOI
2014	Mayo, B., Stringer, A., Bateman, E., Bowen, J., Pietra, C., Cantoreggi, S., & Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective GLP-2 receptor agonist, Elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Supportive Care in Cancer. Miami, USA: Springer Verlag (Germany).
2013	Bateman, E., Wilson, C., Keefe, C., Bowen, J., Wignall, A., Plews, E., & Keefe, D. (2013). Fractionated radiotherapy in a rat model causes dose-dependent changes in collagen deposition, and expression of transforming growth factor β1, Smad3 and smooth muscle actin α1. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany). DOI
2013	Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2013). Development of a walker 256-TC tumour-bearing rat model to study lapatinib-induced mucosal injury. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany). DOI
2013	Radzuan, M., Bateman, E., Bowen, J., Keefe, D., & Stringer, A. (2013). Intestinal Lactobacillus spp. increase following radiotherapy in rats: an unusual finding. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
2013	Bowen, J., White, I., Tuke, J., Logan, R., Richards, A., Mead, K., . . . Coller, J. (2013). IMMUNE GENETIC VARIABILITY IS ASSOCIATED WITH RISK OF SEVERE GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH FLUOROURACIL. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2011	Bateman, E., Bowen, J., Mayo, B., Plews, E., Darby, J., Stringer, A., . . . Keefe, D. (2011). Further characterisation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-induced diarrhoea. Poster session presented at the meeting of Abstracts of the 2011 International MASCC/ISOO Symposium, as published in Supportive Care in Cancer. Athens: Springer-Verlag. DOI
2009	Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). Chemotherapy-induced diarrhoea is associated with a modified microbiome in cancer patients. Poster session presented at the meeting of Abstracts of the Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, as published in Journal of Gastroenterology and Hepatology. Sydney, N.S.W.: Wiley-Blackwell. DOI

Theses

Year Citation

2016 Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis).

Year	Citation
2016	Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis).

Funding

Prof Bowen’s research program has been funded by NHMRC, MRFF, Cancer Council SA, SA Cancer Research Collaborative, Cure Cancer Australia, Australian Dental Research Foundation, the Ray and Shirl Norman Cancer Research Trust, the Royal Adelaide Hospital Research Committee, Flinders University, The Hospital Research Foundation and University of Adelaide. With her co-investigators, funding received has totalled over $5 Million dollars. Industry has been a major funder and continues to be an area of increasing linkage. Current and previous industry partners include Kallyope (PI), GlaxoSmithKline (CI), Helsinn Healthcare (CI), Pfizer Pharmaceuticals (PI), Puma Biotechnology (PI), Zhendong, Pharmaceuticals (AI), CSIRO (CI), AstraZeneca (CI), Danone (CI) and Pantheryx (CI).

Teaching

In 2011, Prof Bowen was appointed to lecturer in Physiology, University of Adelaide, promoted to senior lecturer in 2015, and then associate professor in 2017, which has provided opportunities to teach and train the next generation of researchers. She teaches within the B.HlthMedSc program, particularly involved in delivery of gastrointestinal physiology content. She was Deputy Chair of the Faculty Gender Equity and Diversity committee (2017-2019) and implements inclusive practices for courses she teaches.

Prof Bowen is the Faculty Honours Coordinator and a Senior Postgraduate Coordinator for the School of Biomedicine. In 2024 she also took on the role of Associate Dean, Gender Equity, Diversity and Inclusion. Through these roles she is able to provide leadership in training the next generation of health and medical science researchers.

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2024	Co-Supervisor	Investigating the effect of dietary intake on bone loss and fracture risk in women with breast cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Negin Amin
2024	Co-Supervisor	The Transcranial Magnetic stimulation for Chemotherapy-induced pain Study (TMaC Study)	Master of Philosophy (Medical Science)	Master	Full Time	Mrs Eva Kate Moore
2023	Co-Supervisor	Neuropsychological complications of chemotherapy and the involvement of the endocannabinoid system.	Doctor of Philosophy	Doctorate	Full Time	Miss Olivia Marie Bellas
2022	Co-Supervisor	Examining bone effects of EGFR-targeting breast cancer treatment	Doctor of Philosophy	Doctorate	Full Time	Miss Micaela Jocelyn Quinn
2022	Principal Supervisor	The microbiome in cancer treatment toxicity in the gut	Doctor of Philosophy	Doctorate	Full Time	Mrs Claire Patricia Vieyra
2022	Principal Supervisor	Exploring the effect of diet and gut microbiota on breast cancer using the Dark Agouti Mammary Adenocarcinoma (DAMA) model.	Doctor of Philosophy	Doctorate	Full Time	Ms Ifeoma Julieth Dikeocha
2021	Co-Supervisor	Uncovering novel mechanisms of chemotherapy-induced bone destruction	Doctor of Philosophy	Doctorate	Full Time	Mr Bailey Michael Deverell

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2021 - 2023	Principal Supervisor	An Investigation of Biological Processes Underlying Neratinib-induced Gut Injury	Master of Philosophy (Medical Science)	Master	Full Time	Mr Phu Minh Triet Nguyen
2019 - 2023	Principal Supervisor	The Role of TLR4 in Chemotherapy-Induced Toxicity, Immunity and Tumour Growth	Doctor of Philosophy	Doctorate	Full Time	Mrs Elise Ellen Crame
2019 - 2023	Principal Supervisor	The Microbiota Gut Brain Axis in the Neuropsychological Complications of Chemotherapy Treatment	Doctor of Philosophy	Doctorate	Full Time	Miss Courtney Brooke Subramaniam
2019 - 2021	Principal Supervisor	Exploring the Role of the Gut Microbiome in Toxicity and Response to Radiotherapy for Head and Neck Cancer	Doctor of Philosophy	Doctorate	Full Time	Mrs Ghanyah Hamid Hussein Al-Qadami
2018 - 2022	Principal Supervisor	Exploring the Effects of Toll-Like Receptor 4 Antagonism on Gastrointestinal Mucositis and Tumour Activity	Doctor of Philosophy	Doctorate	Full Time	Miss Shu Yie Janine Tam
2017 - 2021	Principal Supervisor	Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity	Doctor of Philosophy	Doctorate	Full Time	Miss Kate Rebecca Secombe
2016 - 2020	Co-Supervisor	Identifying potential genetic, phenotypic and epigenetic predictive markers in the Toll-like receptor/Interleukin-1 domain innate immune signalling pathway for severe gastrointestinal toxicity risk following 5-Fluorouracil-based therapy	Doctor of Philosophy	Doctorate	Full Time	Miss Samantha Kaitlyn Korver
2016 - 2022	Co-Supervisor	Role of Aquaporin 1 in Diseases and Drug Discovery	Doctor of Philosophy	Doctorate	Full Time	Mr Pak Hin Chow
2014 - 2017	Principal Supervisor	Characterisation and Treatment of Pan-Human Epidermal Receptor Tyrosine Kinase Inhibitor-Induced Gastrointestinal Toxicity	Doctor of Philosophy	Doctorate	Full Time	Ysabella Van Sebille
2013 - 2016	Co-Supervisor	Toll-Like Receptor 4-Dependent Barrier Dysfunction and its Impact on Irinotecan-Induced Gut Toxicity and Pain	Doctor of Philosophy	Doctorate	Full Time	Dr Hannah Rose Wardill
2011 - 2016	Co-Supervisor	In vitro and in vivo Models to assess the mechanism of Lapatinib - Induced Diarrhoea	Doctor of Philosophy	Doctorate	Full Time	Mrs Wan Nor I'zzah Wan Mohamad Zain
2010 - 2015	Principal Supervisor	A Study Linking Toll-like Receptors and Irinotecan-induced Gastrointestinal Mucositis	Doctor of Philosophy	Doctorate	Full Time	Mrs Khloud Ghazi Fakiha
2008 - 2012	Co-Supervisor	Chemotherapy-Induced Mucositis: The Role of Matrix Metalloproteinases and the Extracellular Matrix	Doctor of Philosophy	Doctorate	Full Time	Miss Noor Al-Dasooqi

Board Memberships

Date	Role	Board name	Institution name	Country
2020 - ongoing	Secretary	MASCC Executive Board	MASCC	United States
2018 - ongoing	Board Member	Multinational Association of Supportive Care in Cancer	MASCC	United States
2014 - 2017	Director	Australian Society for Medical Research	Australian Society for Medical Research	Australia

Committee Memberships

Date	Role	Committee	Institution	Country
2014 - ongoing	Member	Multinational Association of Supportive Care in Cancer Governance Committee	-	-
2008 - ongoing	Member	South Australian ASMR committee	-	-

Editorial Boards

Date	Role	Editorial Board Name	Institution	Country
2017 - ongoing	Editor	Inflammopharmacology	Springer	Switzerland
2015 - 2018	Editor	Gastroenterology Research and Practice	Hindawi Publishing Corporation	Egypt

Position: Professor
Phone: 83131374
Email: joanne.bowen@adelaide.edu.au
Fax: 83136387
Campus: North Terrace
Building: Helen Mayo South, floor 2
Org Unit: Medical Sciences

Professor Joanne Bowen

Appointments

Awards and Achievements

Education

Certifications

Research Interests

Journals

Book Chapters

Conference Papers

Conference Items

Theses

Funding

Teaching

Current Higher Degree by Research Supervision (University of Adelaide)

Past Higher Degree by Research Supervision (University of Adelaide)

Board Memberships

Committee Memberships

Editorial Boards

Connect With Me

External Profiles